Lifecore Biomedical Q1 Earnings Call Highlights

1 day ago 2

MarketBeat

Wed, May 6, 2026 astatine 8:07 AM CDT 7 min read

Lifecore Biomedical logo

Key Points

Management added three commercialized tract transportation programs successful Q1 — including a U.S. aesthetics transportation and 2 CDMO agreements (one ophthalmic expansion) — and expects these to make commercialized gross astir 2028, each arsenic mid‑seven‑figure opportunities.
Q1 gross fell 34% to $23.2M with a nett nonaccomplishment of $15.0M and adjusted EBITDA of $1.0M, but the institution chopped SG&A/R&D (cumulative reductions ~$8M since late‑2024) and finished the 4th with astir $38M successful liquidity and affirmative operating currency flow.
Management reaffirmed full‑year 2026 guidance (revenue $120–125M, adjusted EBITDA $20.5–25M) and reiterated long‑term targets of astir a 12% gross CAGR and >25% EBITDA borderline by extremity of 2029.
Interested successful Lifecore Biomedical, Inc.? Here are 5 stocks we similar better.

Lifecore Biomedical (NASDAQ:LFCR) executives highlighted caller commercialized tract transportation wins, continued outgo reductions, and improving liquidity during the company’s first-quarter 2026 net call, portion acknowledging a year-over-year gross diminution tied to antecedently discussed headwinds.

Management reiterates semipermanent targets and reaffirms 2026 outlook

President and CEO Paul Josephs said the institution continued executing connected “each of the 3 pillars” of its maturation strategy: expanding existing commercialized business, advancing improvement programs toward commercialization, and adding caller programs done concern development. Josephs said the institution believes accordant execution supports its longer-term extremity of a 12% gross compound yearly maturation complaint and EBITDA margins supra 25% by the extremity of 2029.

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

Chief Financial Officer Ryan Lake reaffirmed full-year 2026 guidance, calling retired the company’s expectations for:

Total revenue: $120 cardinal to $125 million
Net loss: $35.4 cardinal to $30.9 million
Adjusted EBITDA: $20.5 cardinal to $25 million

Three caller commercialized tract transportation programs added successful the 4th

Josephs emphasized concern improvement momentum successful aboriginal 2026, noting that Lifecore signed 3 caller commercialized tract transportation programs successful the archetypal quarter.

→ 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries

In March, the institution announced a manufacturing services statement with a caller aesthetics lawsuit for the commercialized tract transportation of a marketed, approved merchandise presently manufactured extracurricular the U.S. Josephs said the customer’s extremity is to found U.S.-based manufacturing for products sold domestically, adding that Lifecore believes the merchandise “may make commercialized gross successful 2028.”

Read Entire Article